https://www.selleckchem.com/pr....oducts/pha-848125.ht
01) compared to those with hormone-positive breast cancer. Two variables were identified as significant independent risk factors for FOXP3 positive IDO expression high (adjusted odds ratio (AOR) 5.90; 95% confidence interval (CI) 1.22-28.64; = 0.03) and TNBC (AOR 2.80; 95%CI 0.96-7.95; = 0.05). Our data showed that FOXP3 positive cells might be associated with high expression of IDO in TNBC patients. FOXP3 and IDO co-expression may also suggest its involvement in disease, and evaluation of FOXP3 and IDO expression in TNBC patients ma